{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:13:02Z","timestamp":1792084382138,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR001106"],"award-info":[{"award-number":["KL2TR001106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001108"],"award-info":[{"award-number":["UL1TR001108"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical and Translational Sciences"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.cgh.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T13:27:06Z","timestamp":1533821226000},"page":"380-390.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":183,"title":["AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review"],"prefix":"10.1016","volume":"17","author":[{"given":"Jean-Frederic","family":"Colombel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ajg.2012.260","article-title":"Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis","volume":"107","author":"Halpin","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/apt.13387","article-title":"Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis","volume":"42","author":"Jharap","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.08.001_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/MCG.0000000000000803","article-title":"Small-intestinal bacterial overgrowth is associated with concurrent intestinal inflammation but not with systemic inflammation in Crohn's disease patients","volume":"52","author":"Ricci","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.13333","article-title":"Systematic review: bile\u00a0acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?","volume":"42","author":"Pavlidis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1582-4934.2011.01298.x","article-title":"Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis","volume":"16","author":"Bernardini","year":"2012","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.cgh.2018.08.001_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/PSY.0000000000000470","article-title":"Understanding the gut microbiota in inflammatory and functional gastrointestinal diseases","volume":"79","author":"Sundin","year":"2017","journal-title":"Psychosom Med"},{"key":"10.1016\/j.cgh.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2017.05.056","article-title":"Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing","volume":"153","author":"Chang","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1097\/MIB.0000000000000984","article-title":"Ongoing symptoms in ulcerative colitis patients in remission: irritable bowel syndrome or gastrointestinal symptoms in the absence of inflammation?","volume":"23","author":"Gracie","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41395-018-0021-z","article-title":"Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease","volume":"113","author":"Gracie","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9270(01)04037-0","article-title":"Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Simren","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MIB.0000000000001017","article-title":"Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners","volume":"23","author":"Abdalla","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ajg.2011.377","article-title":"Gastrointestinal and psychological mediators of health-related quality of life in IBS\u00a0and IBD: a structural equation modeling analysis","volume":"107","author":"Naliboff","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2008.01832.x","article-title":"How to do and interpret a rectal examination in gastroenterology","volume":"103","author":"Talley","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/MIB.0000000000001157","article-title":"Fecal calprotectin levels predict histological healing in ulcerative colitis","volume":"23","author":"Patel","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MIB.0000000000000736","article-title":"Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis","volume":"22","author":"Theede","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D'Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1097\/MIB.0000000000001202","article-title":"Fecal calprotectin more accurately predicts endoscopic remission of Crohn's disease than serological biomarkers evaluated using balloon-assisted enteroscopy","volume":"23","author":"Kawashima","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib22","first-page":"53","article-title":"The use of fecal calprotectin in inflammatory bowel disease","volume":"13","author":"Bjarnason","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","article-title":"Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide","volume":"23","author":"Heida","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ibd.21683","article-title":"Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence","volume":"18","author":"Bruining","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn's disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.08.001_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/gut.32.2.179","article-title":"Prevalence of proximal faecal stasis in active ulcerative colitis","volume":"32","author":"Allison","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.08.001_bib27","article-title":"Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation)","author":"James","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol Open"},{"key":"10.1016\/j.cgh.2018.08.001_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2016.09.047","article-title":"Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases","volume":"152","author":"Rieder","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/apt.14526","article-title":"Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation","volume":"47","author":"Gordon","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.08.001_bib30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ecco-jcc\/jjv142","article-title":"Time to look underneath the surface: ulcerative colitis-associated fibrosis","volume":"9","author":"Latella","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ecco-jcc\/jjv153","article-title":"Inflammatory bowel disease and pancreatitis: a review","volume":"10","author":"Ramos","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.08.001_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10620-007-9852-y","article-title":"Prevalence of pancreatic insufficiency in inflammatory bowel diseases. Assessment by fecal elastase\u20131","volume":"53","author":"Maconi","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2018.08.001_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","article-title":"Bile Acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri","year":"2015","journal-title":"Gut Liver"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.08.001_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000268125","article-title":"How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease","volume":"27","author":"Sandborn","year":"2009","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib35","doi-asserted-by":"crossref","first-page":"13999","DOI":"10.3748\/wjg.v20.i38.13999","article-title":"Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment","volume":"20","author":"Sanchez-Montes","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004836-200007000-00015","article-title":"Orocecal transit time and bacterial overgrowth in patients with Crohn's disease","volume":"31","author":"Castiglione","year":"2000","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/jgh.12908","article-title":"Clinical significance of the glucose breath test in patients with inflammatory bowel disease","volume":"30","author":"Lee","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: the\u00a0North American consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.2005.075127","article-title":"Use and abuse of hydrogen breath tests","volume":"55","author":"Simren","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.08.001_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2015.07.032","article-title":"Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth","volume":"14","author":"Lin","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2036.2009.04018.x","article-title":"Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders","volume":"30","author":"Barrett","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.08.001_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2036.2011.04799.x","article-title":"Association of lactose sensitivity with inflammatory bowel disease--demonstrated by analysis of genetic polymorphism, breath gases and symptoms","volume":"34","author":"Eadala","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.08.001_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/00365521.2011.579156","article-title":"Symptoms in\u00a0patients with ulcerative colitis in remission are associated with\u00a0visceral hypersensitivity and mast cell activity","volume":"46","author":"van Hoboken","year":"2011","journal-title":"Scand J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib44","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/0016-5085(87)90255-1","article-title":"Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis","volume":"93","author":"Rao","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1590-8658(01)80038-4","article-title":"Intestinal permeability in patients with Crohn's disease and their relatives","volume":"33","author":"Hollander","year":"2001","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib46","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1007\/s10620-013-2850-3","article-title":"Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission","volume":"58","author":"Perera","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2018.08.001_bib47","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1038\/ctg.2016.22","article-title":"Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets","volume":"7","author":"Halmos","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.08.001_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jgh.13695","article-title":"Use of the low-FODMAP diet in inflammatory bowel\u00a0disease","volume":"32","author":"Gibson","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib49","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjx073","article-title":"Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial","volume":"11","author":"Cox","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.08.001_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13705","article-title":"Non-coeliac gluten sensitivity","volume":"32","author":"Gibson","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.gastro.2017.10.040","article-title":"Fructan, rather than\u00a0gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity","volume":"154","author":"Skodje","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib52","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/ctg.2016.69","article-title":"Psychological interventions for irritable bowel syndrome and inflammatory bowel diseases","volume":"8","author":"Ballou","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41575-018-0001-1","article-title":"Behavioural medicine and gastrointestinal disorders: the promise of positive psychology","volume":"15","author":"Keefer","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MCG.0000000000000049","article-title":"Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease","volume":"48","author":"Iskandar","year":"2014","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib55","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cgh.2017.05.014","article-title":"Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits","volume":"15","author":"Camilleri","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1021\/acsmedchemlett.7b00396","article-title":"Discovery of APD371: identification of a highly potent and selective CB2 agonist for the treatment of chronic pain","volume":"8","author":"Han","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cgh.2018.08.001_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1185\/0300799009117003","article-title":"Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test","volume":"16","author":"Biancone","year":"2000","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2018.08.001_bib58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately\u00a0active Crohn's disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib60","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000358141","article-title":"Is rifaximin effective in maintaining remission in Crohn's disease?","volume":"32","author":"Jigaranu","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib61","first-page":"1220","article-title":"Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial","volume":"44","author":"Gionchetti","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2018.08.001_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.08.001_bib63","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/ctg.2016.32","article-title":"Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome","volume":"7","author":"Acosta","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib64","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/ibd\/izy052","article-title":"No significant association between the fecal microbiome and the presence of irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease","volume":"24","author":"Shutkever","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.gastro.2016.10.004","article-title":"Complementary and alternative medicines used by patients with inflammatory bowel diseases","volume":"152","author":"Cheifetz","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib66","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/MIB.0000000000000333","article-title":"Exercise decreases\u00a0risk of future active disease in patients with inflammatory bowel disease in remission","volume":"21","author":"Jones","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.08.001_bib67","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ajg.2010.480","article-title":"Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial","volume":"106","author":"Johannesson","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib68","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1053\/j.gastro.2018.01.027","article-title":"Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease","volume":"154","author":"Gracie","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib69","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib70","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized\u00a0clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib71","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cgh.2011.03.026","article-title":"Oral bisacodyl is effective and well-tolerated in patients with chronic constipation","volume":"9","author":"Kamm","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.08.001_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A\u00a0double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.08.001_bib73","first-page":"335","article-title":"Loperamide oxide for the treatment of chronic diarrhoea in Crohn's disease","volume":"23","author":"van Outryve","year":"1995","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.cgh.2018.08.001_bib74","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.ejim.2011.08.013","article-title":"Bile acid malabsorption investigated by selenium\u201375-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea","volume":"22","author":"Borghede","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cgh.2018.08.001_bib75","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.08.001_bib76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/gut.2008.163162","article-title":"Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis","volume":"58","author":"Ford","year":"2009","journal-title":"Gut"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518308103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518308103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:27:40Z","timestamp":1761542860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356518308103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1542356518308103"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2018.08.001","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}